MedTrace Logo

Bilateral Uterine Artery Occlusion During Laparoscopic Myomectomy

NCT07352761 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-20

No results posted yet for this study

Summary

The current study is a multiple-arm, single blinded, and controlled randomized trial. It will be conducted in two gynecological endoscopy centers: • ElShatby University Hospital, a tertiary level hospital in Alexandria, Egypt. • Al-Madina Women Hospital, A specialized hospital of Obstetrics and Gynecology, Alexandria, Egypt. Patient selection: women with uterine leiomyomata and planning for laparoscopic myomectomy will be assessed for eligibility then will be enrolled in the trial according to the following inclusion and exclusion criteria, after providing a written informed consent of participation. Outcome variables of the study: The primary outcome is intraoperative blood loss and the change in postoperative hemoglobin. The secondary outcomes of this study are the operative time of performing uterine arteries occlusion and the postoperative ovarian reserve.

Conditions

  • Uterine Fibroids (Leiomyoma)
  • Myomectomy
  • Myomectomy; Surgical Blood Loss

Interventions

PROCEDURE

Temporary clipping of uterine artery

Both uterine arteries will be temporary clipped with a Titanium clip till the end of the myomectomy procedure

PROCEDURE

Temporary occlusive suturing of uterine artery

A "Shoelace" suture will be applied to both uterine arteries and the sutures will be removed at the end of the myomectomy procdure

PROCEDURE

Bipolar coagulation of uterine arteries

Permanent coagulation of both uterine arteries will be performed by Bipolar forceps before the start of the myomectomy procedure

PROCEDURE

Laparoscopic myomectomy only

No occlusion of uterine arteries will be performed. Only Laparoscopic myomectomy will be performed

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2026-01-31
Completion
2026-02-28

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07352761 on ClinicalTrials.gov